GST-HG171/Ritonavir

DRUG3 trials

Sponsors

Fujian Akeylink Biotechnology Co., Ltd.

Conditions

COVID-19 PneumoniaCOVID-19 Respiratory InfectionHealthy Participant

Phase 1

Food Effects of GST-HG171 Tablets Combined With Ritonavir in Healthy Chinese Participants

Fujian Akeylink Biotechnology Co., Ltd.COVID-19 Respiratory Infection

Start: 2023-05-04End: 2023-12-27Target: 18Updated: 2023-10-16

Drug-Drug Interaction Study of Itraconazole With GST-HG171/Ritonavir in Healthy Participants

CompletedNCT06087055

Fujian Akeylink Biotechnology Co., Ltd.Healthy Participant

Start: 2023-05-12End: 2023-08-07Updated: 2023-10-17

Phase 2

Study of GST-HG171/Ritonavir Compared With Placebo in Patients With Mild to Moderate COVID-19

CompletedNCT05656443

Fujian Akeylink Biotechnology Co., Ltd.COVID-19 Pneumonia

Start: 2022-12-19End: 2023-07-14Updated: 2023-10-12

Related Papers

Pharmacokinetic drug-drug interaction between the COVID-19 3CL protease inhibitor GST-HG171 and itraconazole in healthy subjects

Antimicrobial Agents and Chemotherapy2026-05-11

Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial.

2024-04-1013 citations